Breaking News: Everest Medicines Successfully Completes Patient Enrollment for Etrasimod Phase 3 Clinical Trial in Asia
Exciting News in the Biopharmaceutical Field May 17, 2023 SHANGHAI, May 17, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today the completion of patient enrollment in a multi-center Phase 3 clinical trial of etrasimod in…